A Phase 2 Study of BAY 43-9006 in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer
Phase of Trial: Phase II
Latest Information Update: 12 Jun 2013
At a glance
- Drugs Sorafenib (Primary) ; Gemcitabine
- Indications Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 11 Jul 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 11 Jul 2012 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.
- 05 Oct 2006 Status change